Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2006

View Archived Issues

Antitumor effects of pine bark extract in skin carcinogenesis

Sunitinib inhibits RET/PTC oncogenic kinase

Pharmacokinetic study shows feasibility of teriparatide nasal spray in the elderly

Dose proportionality seen with gabapentin GR

AS-1404 slows primary mammary tumor growth in vivo

Phase I/II study investigates Reolysin for recurrent malignant glioma

Biotest to use TAP technology in anticancer therapeutics

Inex revises plan to spin out Tekmira

Medivir offers business round-up

Wyeth affirms safety profile of Effexor XR

Myogen and Novartis extend heart muscle disease research collaboration

Medicis to focus on agreed territories for Ipsen's Reloxin

Phase I trial studies IL-21 with Rituxan in NHL

DynPort begins phase II trial for recombinant plague vaccine candidate

SNX-1012 begins phase II study for chemotherapy-induced oral mucositis

Tigris licenses molecularly targeted therapies for cancer

Anesiva plans NDA filing for 3268

Abbott reports on a new AMPK activator for type 2 diabetes and the metabolic syndrome

Kos files sNDA for new Niaspan CF range of products

Nabi-HB Intravenous recommended for approval

NDA resubmission for Pennsaid

Alzheimer's disease diagnostics described in University of Pennsylvania patent

Novel agents for neurodegenerative diseases and nausea revealed

Recent patents describe new treatment options for cardiovascular diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...